Novavax Makes a $167 Million Purchase to Boost Its Coronavirus Vaccine Production Capacity

After acquiring a Czech company, the clinical-stage biotech will be able to churn out more than 1 billion doses of its SARS-CoV-2 vaccine candidate next year -- if it works.